| 注册
首页|期刊导航|中国药业|基于结构方程模型的药品不良反应监测能力提升研究

基于结构方程模型的药品不良反应监测能力提升研究

赵雪娟 阳剑 李晓玲 何成雪 周明旺 李璠

中国药业2025,Vol.34Issue(4):14-18,5.
中国药业2025,Vol.34Issue(4):14-18,5.DOI:10.3969/j.issn.1006-4931.2025.04.004

基于结构方程模型的药品不良反应监测能力提升研究

Improvement of Adverse Drug Reaction Monitoring Capability Based on Structural Equation Model

赵雪娟 1阳剑 1李晓玲 2何成雪 1周明旺 1李璠3

作者信息

  • 1. 昆明医科大学药学院暨云南省天然药物药理重点实验室,云南 昆明 650500||云南省药物政策研究中心,云南 昆明 650500
  • 2. 云南省药品评价中心,云南 昆明 650500
  • 3. 云南省药物政策研究中心,云南 昆明 650500||昆明医科大学科技成果孵化中心,云南 昆明 650500
  • 折叠

摘要

Abstract

Objective To provide a reference for China's monitoring institutions to carry out adverse drug reaction(ADR)monitoring.Methods Data were obtained by a questionnaire survey,and an empirical study was conducted on the structural equation model of ADR monitoring capability to explore the relevant factors and pathways affecting the ADR monitoring capability of monitoring institutions.Results The institutional mechanism positively affected the ADR monitoring capability through both direct and indirect pathways,with the path coefficients of 0.21 and 0.20 respectively.The resource allocation of monitoring institutions had an indirect positive effect on monitoring capability through intermediary latent variable of professional training,with a path coefficient of 0.41.Professional training had a direct positive effect on monitoring ability,with a path coefficient of 0.75.Conclusion The institutional mechanisms,resource allocation,and professional training of monitoring institutions are the important factors affecting the ADR monitoring capability.It is recommended to improve the construction of institutional mechanisms,increase the investment in human,financial and material resources,and strengthen the professional training of monitoring personnel to improve the monitoring capability.

关键词

药品不良反应监测能力/影响因素/结构方程模型/政策建议

Key words

monitor adverse drug reaction monitoring capability/influencing factor/structural equation model/policy suggestion

分类

药学

引用本文复制引用

赵雪娟,阳剑,李晓玲,何成雪,周明旺,李璠..基于结构方程模型的药品不良反应监测能力提升研究[J].中国药业,2025,34(4):14-18,5.

基金项目

云南省药品不良反应监测评价体系和能力建设研究课题[Q53A00321001418C1]. ()

中国药业

1006-4931

访问量0
|
下载量0
段落导航相关论文